María José Bueno
Cited by
Cited by
Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression
MJ Bueno, IP de Castro, MG de Cedron, J Santos, GA Calin, JC Cigudosa, ...
Cancer cell 13 (6), 496-506, 2008
MicroRNAs and the cell cycle
MJ Bueno, M Malumbres
Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1812 (5), 592-601, 2011
Control of cell proliferation pathways by microRNAs
MJ Bueno, IP de Castro, M Malumbres
Cell cycle 7 (20), 3143-3148, 2008
Multiple E2F-induced microRNAs prevent replicative stress in response to mitogenic signaling
MJ Bueno, MG de Cedrón, U Laresgoiti, J Fernández-Piqueras, ...
Molecular and cellular biology, 2023
Targeting tumor mitochondrial metabolism overcomes resistance to antiangiogenics
P Navarro, MJ Bueno, I Zagorac, T Mondejar, J Sanchez, S Mouron, ...
Cell reports 15 (12), 2705-2718, 2016
Combinatorial effects of microRNAs to suppress the Myc oncogenic pathway
MJ Bueno, M Gómez de Cedrón, G Gómez-López, I Pérez de Castro, ...
Blood, The Journal of the American Society of Hematology 117 (23), 6255-6266, 2011
In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer
I Zagorac, S Fernandez-Gaitero, R Penning, H Post, MJ Bueno, S Mouron, ...
Nature communications 9 (1), 3501, 2018
Essentiality of fatty acid synthase in the 2D to anchorage-independent growth transition in transforming cells
MJ Bueno, V Jimenez-Renard, S Samino, J Capellades, A Junza, ...
Nature communications 10 (1), 5011, 2019
Personalising and targeting antiangiogenic resistance: a complex and multifactorial approach
MJ Bueno, S Mouron, M Quintela-Fandino
British Journal of Cancer, 2017
Down-regulation of specific miRNAs enhances the expression of the gene Smoothened and contributes to T-cell lymphoblastic lymphoma development
E González-Gugel, M Villa-Morales, J Santos, MJ Bueno, M Malumbres, ...
Carcinogenesis 34 (4), 902-908, 2013
The Cdc14B phosphatase displays oncogenic activity mediated by the Ras-Mek signaling pathway
M Chiesa, M Guillamot, MJ Bueno, M Malumbres
Cell Cycle 10 (10), 1607-1617, 2011
FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1
S Mouron, L Manso, E Caleiras, JL Rodriguez-Peralto, OM Rueda, ...
Breast Cancer Research 23 (1), 1-16, 2021
Transient exposure to miR‐203 enhances the differentiation capacity of established pluripotent stem cells
M Salazar‐Roa, M Trakala, M Álvarez‐Fernández, F Valdés‐Mora, ...
The EMBO Journal 39 (16), e104324, 2020
Genetic and epigenetic silencing of MicroRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression
MJ Bueno, IP de Castro, MG de Cedrón, J Santos, GA Calin, JC Cigudosa, ...
Cancer cell 29 (4), 607-608, 2016
Mitochondrial inhibition: a treatment strategy in cancer?
MJ Bueno, JL Ruiz-Sepulveda, M Quintela-Fandino
Current Oncology Reports 23, 1-11, 2021
Emerging role of Fatty acid synthase in tumor initiation: implications for cancer prevention
MJ Bueno, M Quintela-Fandino
Molecular & Cellular Oncology 7 (2), 1709389, 2020
A fatty acid synthase inhibitor shows new anticancer mechanisms
MJ Bueno, R Colomer
EBioMedicine 2 (8), 778-779, 2015
Selective activity over a constitutively active RET-variant of the oral multikinase inhibitor dovitinib: Results of the CNIO-BR002 phase I-trial
M Quintela-Fandino, MJ Bueno, L Lombardia, M Gil, A Gonzalez-Martin, ...
Molecular oncology 8 (8), 1719-1728, 2014
Antiangiogenics and hypoxic response: role of fatty acid synthase inhibitors
M Jose Bueno, J Sanchez, R Colomer, M Quintela-Fandino
Current Drug Targets 17 (15), 1735-1746, 2016
Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A
S Mouron, MJ Bueno, A Lluch, L Manso, I Calvo, J Cortes, ...
Nature Communications 13 (1), 7529, 2022
The system can't perform the operation now. Try again later.
Articles 1–20